Advertisement

Topics

Bristol-Myers Squibb to buy IFM Therapeutics for $300m

19:00 EDT 6 Aug 2017 | Pharmaceutical Technology

Bristol-Myers Squibb (BMS) has entered a definitive agreement to purchase all outstanding capital stock of IFM Therapeutics (IFM) for $300m.

Original Article: Bristol-Myers Squibb to buy IFM Therapeutics for $300m

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb to buy IFM Therapeutics for $300m"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...